These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30014438)

  • 1. Metyrapone treatment in Cushing's syndrome: a real-life study.
    Ceccato F; Zilio M; Barbot M; Albiger N; Antonelli G; Plebani M; Watutantrige-Fernando S; Sabbadin C; Boscaro M; Scaroni C
    Endocrine; 2018 Dec; 62(3):701-711. PubMed ID: 30014438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening Tests for Cushing's Syndrome: Urinary Free Cortisol Role Measured by LC-MS/MS.
    Ceccato F; Barbot M; Zilio M; Frigo AC; Albiger N; Camozzi V; Antonelli G; Plebani M; Mantero F; Boscaro M; Scaroni C
    J Clin Endocrinol Metab; 2015 Oct; 100(10):3856-61. PubMed ID: 26274344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.
    Findling JW; Fleseriu M; Newell-Price J; Petersenn S; Pivonello R; Kandra A; Pedroncelli AM; Biller BM
    Endocrine; 2016 Nov; 54(2):516-523. PubMed ID: 27209465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic accuracy of increased late night salivary cortisol for Cushing's syndrome: a real-life prospective study.
    Ceccato F; Marcelli G; Martino M; Concettoni C; Brugia M; Trementino L; Michetti G; Arnaldi G
    J Endocrinol Invest; 2019 Mar; 42(3):327-335. PubMed ID: 29987756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cushing's Syndrome: Screening and Diagnosis.
    Ceccato F; Boscaro M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):209-15. PubMed ID: 27160717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 10:00-11:00 pm urine cortisol/creatinine ratio. An alternative to late-night salivary cortisol for the diagnosis of Cushing's syndrome.
    Bruno OD; Rossi MA; Juárez-Allen L; Serra HA; Albiero MC
    Medicina (B Aires); 2015; 75(6):373-8. PubMed ID: 26707659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients.
    Daniel E; Aylwin S; Mustafa O; Ball S; Munir A; Boelaert K; Chortis V; Cuthbertson DJ; Daousi C; Rajeev SP; Davis J; Cheer K; Drake W; Gunganah K; Grossman A; Gurnell M; Powlson AS; Karavitaki N; Huguet I; Kearney T; Mohit K; Meeran K; Hill N; Rees A; Lansdown AJ; Trainer PJ; Minder AE; Newell-Price J
    J Clin Endocrinol Metab; 2015 Nov; 100(11):4146-54. PubMed ID: 26353009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late-night salivary cortisol has a better performance than urinary free cortisol in the diagnosis of Cushing's syndrome.
    Elias PC; Martinez EZ; Barone BF; Mermejo LM; Castro M; Moreira AC
    J Clin Endocrinol Metab; 2014 Jun; 99(6):2045-51. PubMed ID: 24628557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concordance of the late night salivary cortisol in patients with Cushing's syndrome and elevated urine-free cortisol.
    Doi SA; Clark J; Russell AW
    Endocrine; 2013 Apr; 43(2):327-33. PubMed ID: 23238876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome.
    Kamenický P; Droumaguet C; Salenave S; Blanchard A; Jublanc C; Gautier JF; Brailly-Tabard S; Leboulleux S; Schlumberger M; Baudin E; Chanson P; Young J
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2796-804. PubMed ID: 21752886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study.
    Detomas M; Altieri B; Deutschbein T; Fassnacht M; Dischinger U
    Front Endocrinol (Lausanne); 2022; 13():903545. PubMed ID: 35769081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone.
    Monaghan PJ; Owen LJ; Trainer PJ; Brabant G; Keevil BG; Darby D
    Ann Clin Biochem; 2011 Sep; 48(Pt 5):441-6. PubMed ID: 21813575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late-night salivary cortisol as a screening test for Cushing's syndrome.
    Raff H; Raff JL; Findling JW
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2681-6. PubMed ID: 9709931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing's disease.
    Trementino L; Cardinaletti M; Concettoni C; Marcelli G; Polenta B; Spinello M; Boscaro M; Arnaldi G
    Pituitary; 2015 Feb; 18(1):60-7. PubMed ID: 24482099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of Late-Night Salivary Cortisol in Evaluating Postoperative Remission and Recurrence in Cushing's Disease.
    Amlashi FG; Swearingen B; Faje AT; Nachtigall LB; Miller KK; Klibanski A; Biller BM; Tritos NA
    J Clin Endocrinol Metab; 2015 Oct; 100(10):3770-7. PubMed ID: 26196950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.
    Bertagna X; Pivonello R; Fleseriu M; Zhang Y; Robinson P; Taylor A; Watson CE; Maldonado M; Hamrahian AH; Boscaro M; Biller BM
    J Clin Endocrinol Metab; 2014 Apr; 99(4):1375-83. PubMed ID: 24423285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line screening tests for Cushing's syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS.
    Ceccato F; Antonelli G; Frigo AC; Regazzo D; Plebani M; Boscaro M; Scaroni C
    J Endocrinol Invest; 2017 Jul; 40(7):753-760. PubMed ID: 28247215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reproducibility and performance of one or two samples of salivary cortisol in the diagnosis of Cushing's syndrome using an automated immunoassay system.
    Carrasco CA; García M; Goycoolea M; Cerda J; Bertherat J; Padilla O; Meza D; Wohllk N; Quiroga T
    Endocrine; 2012 Jun; 41(3):487-93. PubMed ID: 22270871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease.
    Newell-Price J; Pivonello R; Tabarin A; Fleseriu M; Witek P; Gadelha MR; Petersenn S; Tauchmanova L; Ravichandran S; Gupta P; Lacroix A; Biller BMK
    Eur J Endocrinol; 2020 Feb; 182(2):207-217. PubMed ID: 31804965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome.
    Valassi E; Aulinas A; Glad CA; Johannsson G; Ragnarsson O; Webb SM
    Clin Endocrinol (Oxf); 2017 Nov; 87(5):433-439. PubMed ID: 28665508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.